NBCA Journal Club Convenes to Discuss Antithrombin Therapy

NBCA Journal Club Convenes to Discuss Antithrombin Therapy

Launched last year, the NBCA Journal Club highlights groundbreaking research in thrombosis and thrombophilia and features a manuscript author as part of the discussion.

Ultimately, our goal is to further enhance the life-saving medical care that blood clot patients receive. 

Our next session convenes on Tuesday, June 18, 2024 from 2-3 p.m. ET to discuss, Antithrombin Therapy: Current State and Future Outlook,” published in Clinical and Applied Thrombosis/Hemostasis in 2023. Joining us is the paper’s author, George M. Rodgers, III, MD, PhD, Professor of Medicine in the Division of Hematology at the University of Utah School of Medicine.

Learning objectives:

  • Understand the genetic and acquired factors contributing to antithrombin (AT) deficiency and its implications.
  • Explore current treatment strategies for managing AT deficiency.
  • Identify specific patient populations and use cases where AT therapy may be considered and evaluate its potential benefits.
  • Investigate advancements and future directions in research, diagnosis, and treatment approaches for AT deficiency to enhance clinical outcomes and patient care.

The discussion features:

GEORGE M. RODGERS, III, MD, PHD, Professor of Medicine, Division of Hematology, University of Utah School of Medicine

VALENTINA RESTREPO, MD, Hematology Postdoctoral Associate, Yale School of Medicine

ANNA PARKS, MD, Assistant Professor and Director of Thrombosis, University of Utah Division of Hematology

GERALD TRACY, Patient Representative. Read Gerry’s story.

This event is intended for a clinical audience with an interest in thrombosis and thrombophilia, but anyone interested in this topic is welcome to attend.